|
HS Code |
197884 |
| Chemical Formula | C14H20N2O2 |
| Molecular Weight | 248.32 g/mol |
| Appearance | Solid (usually white or off - white) |
| Melting Point | Data may vary, typical range needs further specification |
| Boiling Point | Data may vary, typical range needs further specification |
| Solubility In Water | Low solubility, organic solvents are more suitable |
| Solubility In Organic Solvents | Soluble in common organic solvents like ethanol, dichloromethane |
| Pka | Data may vary, needs more specific determination |
| Flash Point | Data may vary, needs experimental determination |
| Odor | May have a faint, characteristic odor |
As an accredited 1-Pyrrolidinecarboxylic Acid, 3-(2-Aminoethyl)-, Phenylmethyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100 - gram pack of 3-(2 - Aminoethyl)-1 - Pyrrolidinecarboxylic Acid Phenylmethyl Ester. |
| Shipping | The chemical "1 - Pyrrolidinecarboxylic Acid, 3-(2 - Aminoethyl)-, Phenylmethyl Ester" will be carefully packaged to prevent damage. Shipping will follow strict chemical transport regulations, ensuring safe and timely delivery. |
| Storage | Store "1 - Pyrrolidinecarboxylic Acid, 3-(2 - Aminoethyl)-, Phenylmethyl Ester" in a cool, dry place away from direct sunlight. Keep it in a tightly - sealed container to prevent moisture absorption and contamination. Store it separately from incompatible substances like strong oxidizing agents or acids to avoid potential chemical reactions. |
In the enantioselective synthesis of sitagliptin phosphate monohydrate, the (R)-3-aminoethylpyrrolidine fragment functions as the essential chiral amine coupling partner. The protected building block 1-Pyrrolidinecarboxylic Acid, 3-(2-Aminoethyl)-, Phenylmethyl Ester enables precise regiochemical control during the critical amidation step prior to hydrogenolytic unmasking. A production-scale batch process for this intermediate typically couples the free amine—generated in situ by hydrogenolysis of the Cbz group over 10% Pd/C at 1.0–3.0 bar H₂ in a EtOH:H₂O (4:1 v/v) solvent system at 25–35°C in a Hastelloy C-22 stirred autoclave—with 1.0–1.15 molar equivalents of a pre-activated triazolopyrazine acetic acid derivative (commonly its mixed anhydride formed with pivaloyl chloride or an HOBt-active ester). Residual benzyl alcohol generated during deprotection must be monitored by reverse-phase HPLC at 210 nm to remain below 0.15 area% prior to the acylation step, as carryover alcohol competes with the nucleophilic pyrrolidine nitrogen and generates benzyl ester impurities that are difficult to purge downstream. Full compliance with ICH Q7 GMP for active pharmaceutical ingredient intermediates is required; elemental impurities are controlled per ICH Q3D (particularly Pd ≤ 10 µg/g, Ni ≤ 20 µg/g), and residual solvents are validated against USP <467> Class 2 limits for ethanol (5000 ppm) and Class 3 limits for ethyl acetate when used as extractant. The downstream manufacturing sequence continues with condensation of the resulting amide with a β-ketoester (typically 1.0–1.2 eq. of ethyl 2,4,5-trifluorobenzoylacetate) in the presence of TiCl₄ and pyridine to form the enamine, followed by catalytic asymmetric hydrogenation with a chiral Rh(I)/(S)-Binap catalyst at 40–60°C and 40–70 bar H₂ to set the (3R)-stereocenter with >99.0% ee. The terminal finished dosage form is sitagliptin phosphate monohydrate tablets (eq. to 25, 50, or 100 mg free base) for the management of type 2 diabetes mellitus. Process excursions: if the hydrogenolysis temperature exceeds 50°C, pyrrolidine ring hydrogenation can occur, generating N-Cbz-3-(2-aminoethyl)pyrrolidine contaminants that co-crystallize during final API isolation and must be controlled at <0.10% by a dedicated polar-endcapped C18 HPLC method.
Why is the Cbz-protected aminoethylpyrrolidine preferred over N-Boc analogues in solution-phase peptide conjugate synthesis?When 1-Pyrrolidinecarboxylic Acid, 3-(2-Aminoethyl)-, Phenylmethyl Ester is employed as a non-natural amino acid surrogate in solution-phase peptide coupling, the orthogonal benzyl ester allows for C-terminal protection that remains stable to the acidic conditions (e.g., 20–50% TFA/CH₂Cl₂) used to remove N-Boc groups on other residues, thereby avoiding premature deprotection and oligomerization. In a typical fragment condensation, the Cbz-protected pyrrolidine acid is activated with 1.05–1.30 eq. of isobutyl chloroformate and N-methylmorpholine in anhydrous THF at −15 to −5°C to form the mixed anhydride, then added to a solution of the peptide amine nucleophile (stoichiometry 1.0:0.95 anhydride/amine) to afford the amide linkage within 2–6 h. Residual water in the solvent system must be below 500 ppm (Karl Fischer titration) to prevent anhydride hydrolysis; molecular sieves (3Å) are routinely added. Regulatory compliance for materials destined for injectable peptide therapeutics invokes FDA 21 CFR 210/211 and bacterial endotoxin limits of <0.25 EU/mg per USP <85>. Downstream, the phenylmethyl ester is removed by catalytic transfer hydrogenation (Pd/C, ammonium formate) without disturbing the newly formed peptide backbone, yielding the free acid for subsequent conjugation to a drug-loading linker or PEG polymer. The terminal products include proline-mimetic peptide-drug conjugates and integrin-binding cyclic peptides containing a pyrrolidine turn-inducing element; in preclinical development the pyrrolidine ring restricts backbone flexibility and improves metabolic resistance toward intestinal dipeptidyl peptidases.Using the Cbz aminoethylpyrrolidine scaffold as a versatile chiral amine platform, diversification into targeted libraries of dopamine D3 receptor ligands follows a reductive amination pathway with minimal racemization risk. The unblocked (R)-amine obtained after hydrogenolysis is reacted with a library of aryl aldehydes (1.0–1.2 eq. relative to amine) in dichloroethane containing 1.5–3.0 eq. of sodium triacetoxyborohydride at ambient temperature, furnishing tertiary amines in 70–92% isolated yield and with enantiomeric excess retained above 98.5% when monitored by chiral SFC. This step is typically conducted under a nitrogen atmosphere and free of cyanoborohydride to avoid formation of regulated cyanide by-products. The resulting Cbz-protected tertiary amine intermediates can then be crystallized as hydrochloride salts from MTBE/heptane to chemical purity >98.0% (HPLC, 220 nm). Compliance with ISO 9001:2015 quality management systems is standard for kilo-lab and pilot production of building blocks supplied to CNS drug discovery programs. Process mass intensity (PMI) metrics and residual solvent specifications align with ICH Q3C option 2 limits for dichloroethane (5 ppm) and MTBE (5000 ppm). The terminal deliverables are bi-aryl methylamine tool compounds and back-up series candidates for positron emission tomography (PET) tracer development, where the pyrrolidine ring provides conformational constraint governing subtype selectivity.Intermediate for selective cysteine protease inhibitors accessed via Michael acceptorsConjugation of the free (R)-3-(2-aminoethyl)pyrrolidine—liberated quantitatively from the Cbz ester by balloon hydrogenolysis with 5% Pd/BaSO₄ in methanol—with a vinyl sulfone warhead proceeds at 0–5°C in acetonitrile containing 2.5 eq. of triethylamine to deliver the covalent inhibitor scaffold. The stoichiometric ratio of the aminoethylpyrrolidine to the sulfonyl chloride intermediate is maintained at 1.00:0.98 to minimize bis-adduct impurities that form when excess sulfonylating agent reacts with the pyrrolidine nitrogen. Post-quench with aqueous sodium bicarbonate and extraction into dichloromethane yields the Cbz-deprotected vinyl sulfone which, after silica gel chromatography (eluent: CH₂Cl₂/MeOH 95:5), is obtained with 82–88% recovery and sulfonate ester impurity <0.3% (LC-MS). The manufacturing operations are governed by occupational exposure limits for acrylate-type Michael acceptors as defined under REACH and local OSHA airborne threshold limit values; all isolations must be performed in contained filter-dryers with nitrogen inertisation. The downstream synthetic route couples this amine-vinyl sulfone with a dipeptide aldehyde intermediate prepared separately, using a 1.05 eq. of EDC/HOBt in DMF to form the amide, followed by global deprotection with TFA/TIS/H₂O (95:2.5:2.5) to release the crude inhibitor. The terminal product class includes reversible-covalent inhibitors of cathepsin B and cathepsin L, intended for oncology indications, where precise loading of the pyrrolidine core influences off-rate kinetics as measured by surface plasmon resonance. Processing shutdown triggers are activated if the exotherm during vinyl sulfone formation exceeds ΔT=12°C within the first 15 min, as this indicates runaway alkylation of the pyrrolidine ring. |
Competitive 1-Pyrrolidinecarboxylic Acid, 3-(2-Aminoethyl)-, Phenylmethyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Protecting Group | Cleavage Reagent | Typical Conditions | Compatibility with Free Primary Amine |
|---|---|---|---|
| Benzyl carbamate (Cbz) | Hydrogenolysis (H₂, Pd/C) | 1–4 bar H₂, MeOH, 25 °C, 2–6 h | Stable; amine remains free |
| tert-Butyl carbamate (Boc) | Trifluoroacetic acid | 20–50% TFA/CH₂Cl₂, 0–25 °C, 1–3 h | Protonated; requires neutralization |
| 9-Fluorenylmethyl carbamate (Fmoc) | Piperidine | 20% piperidine/DMF, 20 min, 25 °C | Free amine present; may react with dibenzofulvene |
| 2-(Trimethylsilyl)ethyl carbamate (Teoc) | Fluoride ion (TBAF) | 2 equiv TBAF, THF, 50 °C, 4 h | Stable; amine remains free |